Drugs / PF-03654764
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01298505 | Jun 2010 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00989391 | Oct → Dec 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01033396 | Jan → May 2010 | allergic rhinitis | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03654764 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00989391 ↗ |
| Action | Inhibit | “histamine receptor-3 antagonists, such as PF-03654764” PMID 25024716 ↗ Jul 20141“Histamine H3 receptor antagonist” CHEMBL2206292 ↗ |
| Modality | Small molecule | — CHEMBL2206292 ↗ |
| Route | Oral | “given once or twice daily by mouth” NCT00989391 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL2206292 ↗ |